


Mumbai, May 4th, 2026

Wockhardt Reports positive PBT of Rs. 238 Cr for FY 26

FINANCIAL HIGHLIGHTS

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4th Quarter Results for Financial Year 2025-26, today.



Profit before tax Rs.189 cr for Q4FY26 as compared to Rs. (-) 22 cr in the previous year. Profit before tax Rs.238 cr for FY26 as compared to Rs. (-) 16 cr in the previous year.

Q4 FY26 Performance: Revenue growth of 30% compared to previous year, revenue of Rs.965 crore in Q4FY26 compared to Rs.743 Cr in the previous year. EBITDA growth of 147% in EBITDA in Q4FY26 compared to previous year, EBITDA of Rs.196 Cr compared to Rs.79 Cr in the previous year.

FY26 Performance: Revenue growth of 11% compared to previous year, revenue of Rs.3373 crore in FY26 compared to Rs.3033 Cr in the previous year. EBITDA growth of 51% in EBITDA in FY26 compared to previous year, EBITDA of Rs.630 Cr compared to Rs.418 Cr in the previous year.


Financial Performance:

Particulars	Q4 FY26	Q4 FY25	Q3 FY26	FY26	FY25
	Jan - Mar 2026	Jan - Mar 2025	Oct - Dec 2025	Apr - Mar 2026	Apr - Mar 2025
Total Revenue	965	743	888	3,373	3,033
EBITDA before R&D	224	113	204	751	537
EBITDA % to Sales	23.2%	15.2%	23.0%	22.3%	17.7%
R&D	28	34	31	120	119
R&D % to Sales	2.9%	4.6%	3.5%	3.6%	3.9%
EBITDA	196	79	173	630	418
EBITDA Margins %	20.3%	10.7%	19.5%	18.7%	13.8%
Exceptional Items #	22	-	(10)	(85)	-
PBT	189	(22)	67	238	(16)
Profit After Tax	164	(45)	61	199	(57)
PAT Margins %	17.0%	-6.1%	6.9%	5.9%	-1.9%

Exceptional items of Rs. 85 Crores include one-time charges related to restructuring and regulatory compliance, including the impact of US entity liquidation and the New Labour code. Further, during the quarter, Group has executed settlement agreement with chapter 7 trustee for the bankruptcy estate and accordingly, a net charge of Rs. 12.70 Crores was recognized towards settlement amount under Exceptional Items.

During the quarter, pursuant to settlement agreement with Dr. Reddy's, it was agreed to receive Rs. 35.35 Crores towards full and final settlement of all obligation under BTA. This amount has been disclosed as a credit under Exceptional Items for the year ended March 31, 2026.

Biosimilar Highlights:



- The overall Biotech operations for the quarter stood at Rs.252 crore recording a growth of 126% vs Q4FY25. On full year basis the Biotech operations recorded 27% growth while delivering Rs 697 crore. This robust achievement is fuelled by our Emerging Market biotech segment growing at > 34 % on FY25 with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Thailand, Egypt, Algeria and LATAM. Our India Biotech operations continues to grow at double digit pace and is poised for decent growth in the future.
- The Company's strength lies in our robust and end to end well integrated Biotech infrastructure. Looking ahead, the upcoming launch of Insulin analogs over the next few years represents a significant business opportunity, further strengthening our commitment to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.

Business Highlights:

Region-wise Revenue Highlights:

Q3 FY26	Regions	Currency	FY 26	FY 25	Q4 FY26	Q4 FY25
	India & Emerging Market					
146	India Branded Business	INR Cr	523	456	112	95
53	India-Others	INR Cr	217	230	79	111
264	Emerging Market	INR Cr	958	710	320	143
	EU & UK					
29	UK	GBP Mn	111	108	29	27
8	Others	Euro Mn	35	41	10	10
-	USA	USD Mn	0	11	-	1
888	Total revenue		3,373	3,033	965	743

- **India Branded Business** stood at Rs.112 crore in Q4FY26 with a growth of 18% compared to the previous year. On full year basis the business stood at Rs.523 crore in FY26 with a growth of 15% compared to the previous year. The India Business growth was aided by substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK) and the introduction of Regenerative Derma segment.
- **UK region** stood at Rs.349 crore in Q4FY26 with a growth of 20% compared to the previous year. On full year basis the business stood at Rs.1318 crore in FY26 with a growth of 13% compared to the previous year.
- **Emerging Markets region** stood at Rs.320 crore in Q4FY26 with a growth of 124% compared to the previous year. On full year basis the business stood at Rs.958 crore in FY26 with a growth of 35% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth.
- **Irish region** stood at Rs.52 crore in Q4FY26 with a growth of 12% compared to the previous year. On full year basis the business stood at Rs.209 crore in FY26 with a growth of 16% compared to the previous year.

New Products Launch:


- 15 Filings, 13 Approvals and 23 launches in our International Business.
- Biosimilars 11 Filings and 16 Approvals and NCE - 4 Filings & 1 Approval.
- Approval received for EMROK O and EMROK injection in Uganda.

Novel Antibiotics:

Key Updates:

Five Novel Antibiotics from Wockhardt completed Phase 3 Clinical Trials successfully: Emrok®, Emrok O®, Mignaf®, Zaynich® and Foviscu®.

❖ ZAYNICH®:



- EMA granted Accelerated Assessment, recognizing Zaynich's potential to address a significant unmet medical need in the treatment of resistant Gram-negative infections.
- US FDA NDA and EU EMA MAA review progressing smoothly.
- CDSCO Subject Expert Committee approved the clinical data on March 10, 2026; Full approval after CMC data review expected by Q2/Q3 FY 27.

❖ MIQNAF® NAFITHROMYCIN: approved and launched in India.

- Removal of “supply condition” by DCGI – Now facilitates marketing access to wider patient population in need of drug.
- Larger field force deployed to align with the supply condition removal for ease of drug access.
- Increasing acceptance within the clinical community owing to comprehensive coverage of pathogens and shorter course of therapy, facilitating antibiotic stewardship.

**❖ EMROK®/ EMROK O®:**

- Growth rate of 106% vs previous year Q4 and 60% on YTD basis.
- Continues to address critical unmet need in the treatment of difficult-to-manage Gram-positive infections, including bone and joint infections, diabetic foot infections, and pneumonia.
- On track to become the leading brands in the anti-MRSA therapy segment.

**❖ FOVISCU® (WCK 4282):**

- India Phase 3 Clinical Trial completed successfully.
- Underwent combined Phase 2 and Phase 3 program with enrolment of 324 hospitalized cUTI and AP patients wherein more than half of the Enterobacterales isolates (51.4%) were ESBL-positive, and 33.8% of Gram negatives were resistant to cefepime, underscoring the urgent need for stronger first-line treatment options in India, where ESBL prevalence is high.

Intellectual Property Update:

1 Patent was filed and 1 Patent was granted during the quarter ended 31st March 2026 and the cumulative filings till date are 3290 and the Company holds 859 patents.

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It has a comprehensive Drug Discovery team and clinical organisation.


DRUG DISCOVERY PROGRAMME
USFDA QIDP STATUS : 6 ANTI-BACTERIALS

Wockhardt is employing around ~3200 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 78% of its global revenues coming from international businesses.